BioCentury
ARTICLE | Targets & Mechanisms

Managing meningitis

June 26, 2014 7:00 AM UTC

SHX Vaccines is taking a new approach to vaccinating against meningitis-preventing meningococci from binding to host cells in the first place. The company's university collaborators have shown proof of concept for the approach in human tissue explants, including efficacy against serotype B-the bacteria's most common but most intractable subgroup.1

The next step is finding the Neisseria meningitidis epitopes that interact with theirnewly identified human receptor-CD147 (basigin Ok blood group; BSG; EMMPRIN)...